Dashboard
Manage Tickers

ZYME


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

zymeworks-jazz-pharmaceuticals-stocks-climb-on-robust-gastroesophageal-trial-outcomes-and-upcoming-regulatory-plans
Zymeworks, Jazz Pharmaceuticals Stocks Cli...
11/17/2025 17:09:52

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
11/17/2025 17:06:53

jazz-pharmaceuticals-sigma-lithium-zymeworks-and-other-big-stocks-moving-higher-on-monday
Jazz Pharmaceuticals, Sigma Lithium, Zymew...
11/17/2025 16:39:23

Core News & Articles
Market-Moving News for November 17th
11/17/2025 12:23:00

GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in the company. ZYME: 61% | Zy...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
11/17/2025 12:06:42

Core News & Articles
Zymeworks And Partners Report Statisticall...
11/17/2025 11:18:46

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab a...

wells-fargo-maintains-equal-weight-on-zymeworks-raises-price-target-to-17
Wells Fargo Maintains Equal-Weight on Zyme...
11/07/2025 18:54:52

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Equal-Weight and raises the price target fro...

zymeworks-q3-eps-026-beats-035-estimate-sales-27614m-miss-29460m-estimate
Zymeworks Q3 EPS $(0.26) Beats $(0.35) Est...
11/06/2025 21:19:34

Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.35) by ...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

5-analysts-have-this-to-say-about-zymeworks
5 Analysts Have This To Say About Zymeworks
10/24/2025 12:01:42

zymeworks-announces-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor-alpha-at-aacr-nci-eortc-conference
Zymeworks Announces Preliminary Results Fr...
10/23/2025 16:32:55

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced...

jp-morgan-maintains-overweight-on-zymeworks-raises-price-target-to-23
JP Morgan Maintains Overweight on Zymework...
10/16/2025 11:48:53

JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $20 to $23.

broadcom-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-tuesday
Broadcom To Rally More Than 12%? Here Are ...
10/14/2025 12:25:08

this-rpm-international-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday
This RPM International Analyst Turns Bulli...
10/14/2025 12:00:55

hc-wainwright--co-upgrades-zymeworks-to-buy-raises-price-target-to-26
HC Wainwright & Co. Upgrades Zymeworks to ...
10/14/2025 11:15:14

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks (NASDAQ:ZYME) from Neutral to Buy and raises the price targe...

zymeworks-to-present-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor--at-aacr-nci-eortc-conference-2025
Zymeworks To Present Preliminary Results F...
10/13/2025 20:02:36

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with ...

b-riley-securities-initiates-coverage-on-zymeworks-with-buy-rating-announces-price-target-of-30
B. Riley Securities Initiates Coverage On ...
10/10/2025 13:28:05

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating and announces Pri...

zymeworks-pulls-plug-on-early-stage-cancer-potential-as-therapy-unlikely-to-provide-benefit
Zymeworks Pulls Plug On Early-Stage Cancer...
09/02/2025 16:30:13

Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, includin...

zymeworks-discontinues-clinical-development-of-mesothelin-directed-t-cell-engager-zw171-following-phase-1-dose-escalation-review
Zymeworks Discontinues Clinical Developmen...
09/02/2025 10:06:15

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/22/2025 21:07:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION